Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects

World Journal of Gastroenterology

Volumn 10, Issue 5, 2004, Pages 654-659

  He, Chao ^a   Lao, Wei Feng ^a   Hu, Xiao Tong ^a   Xu, Xiang Ming ^b   Xu, Jing ^a   Fang, Bing Liang ^c  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOVIRUS VECTOR; BETA GALACTOSIDASE; COMPLEMENTARY DNA; PROTEIN BAX; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CELL ASSAY; CELL FRACTIONATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DNA TRANSFER; FIBROBLAST; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE SEQUENCE; GENE TRANSFER; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; TUMOR CELL LINE; VIRAL GENE DELIVERY SYSTEM;

EID: 1542685203     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i5.654     Document Type: Article

References (41)

1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-12690
3. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255-260
4. Griffith TS, Lynch DH. TRAIL: A molecule with multiple receptors and control mechanism. Curr Opin Immunol 1998; 10: 559-563
5. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162
6. Lacour S, Micheau O, Hammann A, Drouineaud V, Tschopp J, Solary E, Dimanche- Boitrel MT. Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 2003; 22: 1807-1816
7. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell line. Cancer Res 1999; 59: 734-741
8. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163
9. Fang BL, Ji L, Bouvet M, Roth JA. Evaluation of GAL4/TATA in vivo induction of transgene expression by adenovirally mediated gene codelivery. J Biol Chem 1998; 273: 4972-4975
10. Kagawa S, Gu J, Swisher SG, Lin J, Roth JA, Lai D, Stephens LC, Fang B. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. Cancer Res 2000; 60: 1157-1161
11. Wu MC. Clinical research advances in primary liver cancer. World J Gastroenterol 1998; 4: 471-474
12. Habib NA, Ding SF, Masry R, Mitry RR, Honda K, Michail NE, Dalla Serra G, Izzi G, Greco L, Bassyouni M, el-Toukhy M, Abdel-Gaffar Y. Preliminary report: The short term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev 1996; 20: 103-107
13. Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M, Curley SA, Yu Y, Hunt KK, Fang B. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 2002; 21: 8020-8028
14. Ahmad M, Shi Y. TRAIL-inducing apoptosis of thyroid cancer cells: Potential for therapeutic intervention. Oncogene 2000; 19: 3363-3371
15. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833-2840
16. Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene 2001; 20: 5789-5798
17. Lincz LF, Yeh TX, Spencer A. TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 2001; 15: 1650-1657
18. Chen Q, Gong B, Mahmoud-Ahmed AS, Zhou A, Hsi ED, Hussein M, Almasan A. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 2001; 98: 2183-2192
19. Burns TF, El-Deiry WS. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL- sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 2001; 276: 37879-37886
20. Trauzold A, Wermann H, Arlt A, Schutze S, Schafer H, Oestern S, Roder C, Ungefroren H, Lampe E, Heinrich M, Walczak H, Kalthoff H. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001; 20: 4258-4269
21. Ibrahim SM, Ringel J, Schmidt C, Ringel B, Muller P, Koczan D, Thiesen HJ, Lohr M. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001; 23: 72-79
22. Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A 1997; 94: 13862-13867
23. Okuyama T, Fujino M, Li XK, Funeshima N, Kosuga M, Saito I, Suzuki S, Yamada M. Efficient Fas-ligand gene expression in rodent liver after intravenous injection of a recombinant adenovirus by the use of a Cre-mediated switching system. Gene Ther 1998; 5: 1047-1053
24. Koch PE, Guo ZS, Kagawa. S, Gu J, Roth RA, Fang B. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. Mol Ther 2001; 3: 278-283
25. Pan G, Ni J, Yu G, Wei YF, Dixit VM. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signaling. FEBS Lett 1998; 424: 41-45
26. He C, Xu XM, Hu XT, Fang BL. Experimental study of effects of bax gene on human colorectal cancer cell line HT-29. Zhonghua Xiaohua Zazhi 2002; 22: 535-538
27. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA, Curley SA, Stephens LC, Fang B. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001; 61: 3330-3338
28. Xu XM, He C, Hu XT, Fang BL. Tumor necrosis factor-related apoptosis-inducing ligand gene on human colorectal cancer cell line HT29. World J Gastroenterol 2003; 9: 965-969
29. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997: 277: 815-818
30. Sheridan JP, Masters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Grey CL, Baker K, Wood WI, Goddard AD, Godowiski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821
31. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, Walczak H. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000; 60: 553-559
32. Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand is in dependent of FADD but blocked by CrmA. Curr Biol 1996; 6: 750-752
33. Wu XX, Kakehi Y, Mizutani Y, Nishiyama H, Kamoto T, Megumi Y, Ito N, Ogawa O. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer 2003; 104: 409-417
34. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564-567
35. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A. Differential hepatocyte toxicity of recombinant App2L/TRAIL versions. Nature Med 2001; 7: 383-385
36. Qin JZ, Chau BN, Bonish B, Nickoloff BJ. Avoiding premature apoptosis of normal epidermal cells. Nature Med 2001; 7: 385-386
37. Ozoren N, Kim K, Burns TF, Dicker DT, Moscioni AD, El-Deiry WS. The caspase-9 inhibitor Z-LEDH-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000; 60: 6259-6265
38. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997; 277: 955-959
39. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165: 2886-2894
40. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113
41. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 5386-5397